David Lamond bought $69k of QNCX
director at Quince Therapeutics, Inc.. 67,881 shares at an average of $1.02, traded Dec 12, 2023, filed Dec 14, 2023.
Score components
- +15RoleDirector
- +8Trade size$69k at market
- 0Relative to holdingsHoldings up 3.0%
- +8Price context44% below the 52-week high
- 0ClusterNo other insider buying within 14 days
- +5Repeat buying3 buys in 90 days
- 0Track recordToo few past buys to judge (0 with prices)
What happened after comparable buys
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
This signal so far: 1m +33.0%, 3m +12.6%, 6m -32.2%.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001209191-23-058694, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Dec 12, 2023 | POpen-market purchase Common Stockindirect: By Blue Devil Trust dated 12/03/2010 | +300 | $1.00 | $300 | 2,279,964 | Dec 14, 2023 |
| Dec 12, 2023 | POpen-market purchase Common Stock | +22,327 | $1.02 | $23k | 2,302,291 | Dec 14, 2023 |
| Dec 13, 2023 | POpen-market purchase Common Stockindirect: By Blue Devil Trust dated 12/03/2010 | +22,627 | $1.00 | $23k | 2,324,918 | Dec 14, 2023 |
| Dec 14, 2023 | POpen-market purchase Common Stockindirect: By Blue Devil Trust dated 12/03/2010 | +22,627 | $1.04 | $24k | 2,347,545 | Dec 14, 2023 |
Related signals
Other insiders at Quince Therapeutics, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 46Moderate | QNCXsell Quince Therapeutics, Inc. | Luca Benatti director | $174k 50,000 shares | -56% | |
| 64Notable | Quince Therapeutics, Inc. | Dirk Thye CEO AND CHIEF MEDICAL OFFICER | $107k 154,500 shares | +22% | |
| 58Moderate | Quince Therapeutics, Inc. | Charles S. Ryan PRESIDENT | $31k 48,387 shares | +65% | |
| 46Moderate | Quince Therapeutics, Inc. | Brendan Hannah CHIEF BUSINESS OFFICER AND COO | $24k 38,924 shares | +15% | |
| 35Weak | QNCXbuy Quince Therapeutics, Inc. | David Lamond director | $58k 57,369 shares | +3% | |
| 29Weak | QNCXbuy Quince Therapeutics, Inc. | David Lamond director | $41k 43,134 shares | +2% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.